Moneycontrol PRO

Buy Sun Pharmaceutical Industries; target of Rs 1210: ICICI Direct

ICICI Direct is bullish on Sun Pharmaceutical Industries recommended buy rating on the stock with a target price of Rs 1210 in its research report dated February 01, 2023.

February 02, 2023 / 03:31 PM IST
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Sun Pharmaceutical Industries

Sun is the world’s fourth largest generics/specialty pharma company with 43 manufacturing sites at its disposal addressing segments like specialty products, branded generics, complex generics, pure generics and APIs. With a market share of 8.6%, Sun is ranked No. 1 in domestic formulations. It enjoys leadership position in 11 specialties based on prescription • Revenue break-up Q3FY23: US formulation~31%, Indian branded~31%, Emerging markets~19%, RoW~14%, API & Others~5%.


We maintain BUY as 1) Global specialty portfolio continues to maintain momentum, 2) Growth in India formulations from new launches and field force expansion and 3) Calibrated cost approach including R&D spend. Valued at Rs 1210 i.e. 28x P/E on FY25E EPS of Rs 43.2.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Sun Pharmaceutical Industries - 01 -01-2023 - ic

Broker Research
first published: Feb 2, 2023 03:31 pm